{
    "clinical_study": {
        "@rank": "156234", 
        "arm_group": [
            {
                "arm_group_label": "MK-3102", 
                "arm_group_type": "Experimental", 
                "description": "MK-3102 25 mg administered orally once weekly for 52 weeks (24 weeks during Period A and 28 weeks during Period B).   Participants continued pre-study basal medication throughout the duration of the study."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo to MK-3102 administered orally once weekly for 24 weeks (Period A) followed by MK-3102 25 mg administered orally once weekly for 28 weeks (Period B).  Participants continued pre-study basal medication throughout the duration of the study."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will examine the safety and efficacy of the addition of MK-3102 in Japanese\n      participants with type 2 diabetes mellitus who have inadequate glycemic control on\n      diet/exercise therapy and oral antihyperglycemic agent monotherapy."
        }, 
        "brief_title": "MK-3102 Phase III Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015 AM1)", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has type 2 diabetes mellitus\n\n          -  Has inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic\n             agent monotherapy\n\n        Exclusion Criteria:\n\n          -  History of type 1 diabetes mellitus or a history of ketoacidosis\n\n          -  History of any of the following medications: TZD (for participants whose basal\n             medication is not TZD) and/or insulin within 12 weeks prior to study participation,\n             MK-3102 anytime"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "585", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697592", 
            "org_study_id": "3102-015", 
            "secondary_id": "132242"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MK-3102", 
                    "Placebo"
                ], 
                "description": "MK-3102 25 mg capsule administered orally once weekly", 
                "intervention_name": "MK-3102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo to MK-3102 25 mg capsule administered orally once weekly", 
                "intervention_name": "Matching placebo to MK-3102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-3102", 
                    "Placebo"
                ], 
                "description": "Participants continue basal medication at their pre-study dosage (dosage may be up-titrated during the study only if needed for rescue therapy). Basal medication includes any of the following: sulfonylureas (gliclazide, glibenclamide or glimepiride), glinides (nateglinide, mitiglinide or repaglinide), biguanides (metformin), thiazolidinediones (TZDs) (pioglitazone), alpha-glucosidase inhibitors (acarbose, voglibose or miglitol).", 
                "intervention_name": "Basal medication", 
                "intervention_type": "Drug", 
                "other_name": [
                    "gliclazide (Glimicron\u00ae)", 
                    "glibenclamide (Euglucon\u00ae, Daonil\u00ae)", 
                    "glimepiride (Amaryl\u00ae)", 
                    "nateglinide (Starsis\u00ae, Fastic\u00ae, Starlix\u00ae)", 
                    "mitiglinide (Glufast\u00ae)", 
                    "repaglinide (Surepost\u00ae, Prandin\u00ae)", 
                    "metformin (Metgluco\u00ae, Glycoran\u00ae, Fortamet\u00ae, Glucophage\u00ae, Glucophage\u00ae XR, Glumetza\u00ae, Riomet\u00ae)", 
                    "pioglitazone (Actos\u00ae)", 
                    "acarbose (Glucobay\u00ae, Precose\u00ae)", 
                    "voglibose (Basen\u00ae)", 
                    "miglitol (Seibule\u00ae, Glyset\u00ae)"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Miglitol", 
                "Nateglinide", 
                "Pioglitazone", 
                "Repaglinide", 
                "Mitiglinide", 
                "Voglibose", 
                "Glyburide", 
                "Gliclazide", 
                "Hypoglycemic Agents", 
                "Metformin", 
                "Acarbose"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blinded Study and Subsequent Open-label, Extension Study to Assess the Safety and Efficacy of Addition of MK-3102 in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Oral Antihyperglycemic Agent Monotherapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of participants who experienced at least one adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "measure": "Percentage of participants who experienced at least one adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "measure": "Percentage of participants who discontinued from the study due to an adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "measure": "Percentage of participants who discontinued from the study due to an adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks"
            }
        ], 
        "removed_countries": {
            "country": "Japan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697592"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change from baseline in hemoglobin A1c (HbA1c)", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 24"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}